Ribon Therapeutics Announces Presentations at the American Association for Cancer Research 2022 Annual Meeting
- New clinical biomarker data from Phase 1 monotherapy trial of RBN-2397 provide evidence for immune cell infiltration in patient tumors upon treatment, providing strong rationale for combining with immune checkpoint inhibitors
- Preclinical studies provide further insight into the cancer cell-intrinsic mechanism of RBN-2397’s antitumor activity
Cambridge, MA – April 11, 2022 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that an oral presentation and poster presentation for RBN-2397, the Company’s lead development candidate, was presented today, April 11, 2022, at the American Association for Cancer Research (AACR) Annual Meeting 2022 taking place in New Orleans, Louisiana. RBN-2397 is a small molecule inhibitor of PARP7 being evaluated in multiple clinical trials for the treatment of cancer.
“We are pleased to present additional clinical and preclinical data from our RBN-2397 program that provides further evidence that PARP7 inhibition induces a tumor-specific immune response by activating Type I interferon signaling pathways,” said Prakash Raman, Ph.D., President and Chief Executive Officer, Ribon Therapeutics. “Combining RBN-2397 with immune checkpoint inhibitors is anticipated to further potentiate the immune response in a variety of tumor types, and we look forward to evaluating this in our ongoing Phase 1b/2 trial of RBN-2397 in combination with pembrolizumab in patients with squamous cell carcinoma of the lung.”
Details for the AACR Annual Meeting 2022 presentations are as follow:
Abstract Title: RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in patient tumors
Abstract ID: 1836
Session Title: Mechanism of Drug Action 1
Date & Time: Monday, April 11, 2022, from 1:30 p.m. to 5:00 p.m. CDT
- RBN-2397 induces tumor-specific interferon pathway activation and increases immune cell infiltration into patient tumors being evaluated in a Phase 1 trial of RBN-2397 as a monotherapy, providing evidence for the induction of an adaptive immune response.
- This data confirms the tumor-intrinsic, immunomodulatory mechanism of action of RBN-2397, and supports additional studies of RBN-2397 in combination with immune checkpoint inhibitors.
Abstract Title: PARP7 inhibitor RBN-2397 increases tumoral IFN signaling leading to various tumor cell intrinsic effects and tumor regressions in mouse models
Abstract ID: 2154
Session Title: Emerging New Anticancer Agents
Date & Time: Monday, April 11, 2022, from 2:30 p.m. to 4:30 p.m. CDT
- In preclinical cancer models, RBN-2397 leads to tumor regression by activation of Type I interferon signaling resulting in antitumor immunity, as well as tumor intrinsic mechanisms including cellular senescence, interference with autophagy, and changes in tumor cell metabolism
- The data demonstrate that both tumor intrinsic and immune system mediated effects of RBN-2397 contribute to its antitumor activity.
The AACR presentations are available on its corporate website via the following link: https://ribontx.com/publications/.
RBN-2397 is an orally available small molecule inhibitor of PARP7 being developed for the treatment cancer. PARP7 is upregulated in response to cellular stress, including genomic instability in cancers, and acts as a brake on the cellular stress response by negatively regulating the Type I interferon response. By inhibiting PARP7 in tumor cells, RBN-2397 has been shown to directly inhibit cellular proliferation and restore interferon signaling to stimulate an innate and adaptive antitumor immune response. RBN-2397 is currently in a Phase 1 clinical trial as a monotherapy in patients with advanced solid tumors and in a Phase 1b/2 clinical trial in combination with pembrolizumab. PARP7 is overexpressed in a number of tumors, including squamous cell carcinoma of the lung, or SCCL, which represents approximately 30% of all non-small cell lung cancers.
About Ribon Therapeutics
Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. Ribon’s portfolio includes two oral first-in-class clinical programs, RBN-2397 (a PARP7 inhibitor) and RBN-3143 (a PARP14 inhibitor), targeting broad indications in oncology and inflammatory diseases. The company explores novel areas of biology to develop effective treatments for patients with limited therapeutic options and has active clinical programs in oncology and inflammatory disease. Leveraging our proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform, we are building a pipeline of selective, small molecule inhibitors to numerous NAD+-utilizing enzymes, beginning with monoARTs (mono-ADP-ribosyltransferase), which have applications across multiple therapeutic areas. Ribon is located in Cambridge, Massachusetts. For more information, visit https://ribontx.com/.